AbbVie says Trump pressing for larger Medicare drug price cuts

By Patrick Wingrove and Puyaan Singh (Reuters) -AbbVie said on Friday the Trump administration was pushing for steeper cuts in this year's Medicare drug price negotiations, which in 2024 yielded discounts of as much as 79%. AbbVie's irritable bowel syndrome drug Linzess and antipsychotic medication Vraylar were among the 15 drugs targeted this year for Medicare price negotiations that end on Saturday. The company said these cuts, which have yet to be made public and will take effect in 2027, would not a ...